Sorry, you need to enable JavaScript to visit this website.

Skip to main content

Search

Infectious Diseases & Vaccines: Leadership

Infectious Diseases & Vaccines: Leaders

 

Infectious Diseases & Vaccines

Infectious Diseases & Vaccines

The structure of HIV
The structure of HIV

Johan Van Hoof, M.D. received his medical degree (cum laude) from the University of Antwerp, Belgium, and was a research fellow in the Department of Anatomy and Embryology at Rijksuniversitair Centrum Antwerpen, Belgium. He studied business management at Krauthammer International School and the International Executive Programme INSEAD, Fontainebleau, France.

Johan joined the Johnson & Johnson Family of Companies in April 2005 as Vice President, Data Management and Early Clinical Development. Following roles as Chief Operating Officer (COO) of Johnson & Johnson Pharmaceutical Research, LLC, and Head of the Global Development Organization, he was appointed Global Therapeutic Area Head for Infectious Diseases & Vaccines in 2010. Since 2011, in addition, he has been overseeing Research & Development at Crucell, the specialized vaccine company acquired, as their COO and Managing Director.

Before joining the Johnson & Johnson Family of Companies, Johan acquired more than 20 years of experience in the vaccine industry, having worked with Pasteur Mérieux Connaught, Chiron Vaccines and GlaxoSmithKline (GSK) Biologicals. During this period, he held leadership roles with increasing responsibilities, including Head New Product Development at GSK Biologicals. Johan was actively involved in the development and licensing of a new generation of childhood and adult vaccines in disease areas such as pertussis (pediatric combined vaccines), meningitis, rotaviral diarrhea, hepatitis, flu and HPV.

Johan Van Hoof, M.D.

Global Therapeutic Area Head, Infectious Diseases & Vaccines

Lawrence Blatt, Ph.D. is responsible for co-leading the Infectious Diseases & Vaccines (IDV) Therapeutic Area at Janssen Research & Development. Prior to joining the Johnson & Johnson Family of Companies, Lawrence founded and was President and Chief Executive Officer of Alios BioPharma, Inc., the clinical stage biopharmaceutical company focused on developing therapies for viral diseases that was acquired by Johnson & Johnson in 2014. He was named as key inventor on several Alios patents and won the 2012 Ernst & Young Entrepreneur of the Year Award for Life Sciences.

Lawrence spent 30 years in pharmaceutical research and development with a specific focus on the biology of the immune system, antiviral therapies and relevant therapeutic interventions. Before forming Alios, he was Chief Scientific Officer of InterMune, Inc. where he led the discovery and development of an HCV protease inhibitor partnered with Roche. From 1998 to 2002, Lawrence was Vice President of Research at SIRNA. From 1996 to 1998, he served as Vice President, Product Development at National Genetics Institute where he pioneered the use of molecular diagnostics to drive therapeutic treatment decisions for viral infections. He began his career at Amgen where he was ultimately Head of Interferon Research and also Development Team Leader for a consensus interferon product leading to approval by the United States Food and Drug Administration (FDA).

Lawrence earned his B.S. in Microbiology from Indiana University, a Master's in Business Administration at the California State University, Northridge, and a Doctorate in Public Health Administration at the University of La Verne, California.

Lawrence Blatt, Ph.D.

Global Therapeutic Area Head, Infectious Diseases & Vaccines

Toon Overstijns is the Global Commercial Strategy Leader for the Infectious Diseases & Vaccines Therapeutic Area.

Toon started his career in Janssen as Area Managing Director for Janssen Central and Eastern Europe. He later served for five years as Director of Janssen Germany, where he was also Director of the German Pharmaceutical Research Industry Association. Prior to this appointment, he was President of Janssen Japan for four years.

Toon studied at the University of Leuven in Belgium, University of Stellenbosch in South Africa, and Stanford University in California. He holds a doctoral degree and a Master’s in Business Administration.

Toon Overstijns

Global Commercial Strategy Leader, Infectious Diseases & Vaccines